1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to presentations of Senzime’s first quarter 2026 report

Senzime invites investors, analysts, and media to presentations of the first quarter report for 2026 on April 22. The report will be published at 08.00 am CEST the same day.

Philip Siberg, CEO of Senzime, will present the Q1 report through a webcast that can be seen from 09.00 am CEST on Senzime’s website https://www.senzime.com/investors
 
A Live Q&A, hosted by Gustaf Meyer, analyst at Redeye, will be aired at 11:00 am CEST via Redeyes platform. A recording of the Q&A will be published later the same day via Redeye’s website https://www.redeye.se/company/senzime
 
Questions for the Q&A interview can be emailed in advance, no later than April 22, 10:00 am CEST, to gustaf.meyer@redeye.se

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
 
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Invitation to presentations of Senzime’s first quarter 2026 report

Datum 2026-04-17, kl 10:00
Källa MFN
Bifogade filer
Invitation to presentations of Senzime’s first quarter 2026 report